Role of Oral Corticosteroids in Treatment of Home Isolated COVID-19 Patients | ||||
Egyptian Journal of Medical Microbiology | ||||
Article 3, Volume 30, Issue 4, October 2021, Page 19-24 PDF (225.48 K) | ||||
Document Type: New and original researches in the field of Microbiology. | ||||
DOI: 10.21608/ejmm.2021.197450 | ||||
View on SCiNiTO | ||||
Authors | ||||
Mohammed A. Aboelmagd1; Mariam Hassan 2; Eman R. Hamed3; Mohamed M. Abdo4; Nageh Louis1 | ||||
1Lecturer of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt | ||||
2Resident of Gastroenterology, Ahmed Maher Teaching Hospital, Cairo, Egypt | ||||
3Assistant Professor of Pulmonary Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt | ||||
4Assistant Professor of Internal Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt | ||||
Abstract | ||||
Background: There is a debate over the efficacy of corticosteroids (CS) in management of Coronavirus diseases 2019 (COVID-19); yet, few are declared about its role in treatment of mild conditions. Objectives: in this study, we aimed at investigating the role of corticosteroids in mild cases of COVID-19. Methodology: in a case control study, we included 100 patients with mild COVID-19. The incidence of improvement, disappearance of symptoms, appearance of new symptoms and deterioration were compared between cases and control group. Results: More than three fourths of the study participants showed improvement of symptoms, with disappearance of symptoms in 64% and 85% of group 1 and group 2, respectively. Only few numbers of patients deteriorated. Noticeably, a remarkable number of patients expressed new symptoms by the end of the study. Conclusions: corticosteroids has no role in clinical progression of cases with mild COVID-19. CS use should be reserved for severe symptoms of COVID-19. | ||||
Keywords | ||||
COVID-19; Corona virus; SARS-CoV-2; Corticosteroids | ||||
Statistics Article View: 453 PDF Download: 903 |
||||